– Norwegian technology is fully developed. We have obtained patent rights. And we recently demonstrated the technology’s benefit with a research group in Italy, says Jan-Terry Andersen, professor in the Department of Clinical Medicine at the University of Oslo, and research group leader at Oslo University Hospital.
The technology is now embodied in the development of drugs that can improve the treatment of hemophilia. The research group found that by attaching superalbumin to various clotting factors, the duration of the effect could be prolonged.
long half life
– Can you tell us about the technology?
All protein-based drugs, except for antibodies, have a short effect in the body. This means that it must be given in large doses and frequently, as in the treatment of chronic diseases. It’s a huge burden for patients, and there’s a cost perspective here as well.
Norwegian researchers publish study on recently patented biomedical technology, developed at OUS
In developing the technology, we investigated a biological mechanism that regulates the long half-life of albumin. It is a protein produced in the liver and has a half-life of three weeks. It is quite long compared to other proteins, which have a half-life of hours or days.
– We studied the reason for this and found that the body has some kind of rescue mechanism for this particular protein. Almost all cells of the body have receptors that bind albumin and keep it from being broken down by cells. Instead, the albumin is pushed out of the cells and back into the bloodstream.
Andersen says the starting point was that if researchers could fully understand the biological mechanism, they could leverage the knowledge to develop a biomedical technology that could also keep protein-based drugs from being quickly removed from the body.
We’ve studied the mechanism down to the atomic level for nearly 15 years, and used the insight to design a new type of protein that does the job better than natural albumin. This now allows us to associate the designed album variant with two drug candidates.
It may be possible to make new protein drugs or improve existing ones. Even the candidate drugs that were placed in the tray because the desired effect was not achieved.
Cancer and Infectious Diseases Screening
It is Andersen, along with two others who are the main inventors of the technology.
And there are many who are now contributing to technology testing, Andersen says.
Technology is versatile and can be used often. Bleeding disease is a complex disease that lends itself to demonstrating what technology can achieve. We recently published two articles explaining how technology can be used to provide better long-term preventive medicine aimed at treating serious hemophilia.
The research group collaborated with a hematology research group in Ferrara, Italy, to represent the technology.
Bleeding disease is a group of inherited diseases that share a decreased ability of the blood to clot and that there is an increased tendency to bleed joints and muscles. There are many such diseases, but the hemophilia group includes only two; Hemophilia A and B. In hemophilia A there is a decrease in clotting factor VIII, in hemophilia B there is a decrease in clotting factor IX. About 400 people with hemophilia A or B have been registered in Norway, according to Norsk Lexicon.
We are now testing technology in many medical fields, including cancer and infectious diseases. In the near future we will publish the first article on how we developed and designed vaccine design technology.
Establishes own company
When is the technology expected to be used in medicines and patients?
– The technology is new. So far we have done preclinical studies in animals. Human studies have not yet been conducted. We have great faith in technology, and are currently working with international companies to test the technology.
– We are also in the process of setting up a separate company, and are open to further cooperation with the industry. It’s a very exciting phase we’re in right now, and it looks promising.
The research group has also shown that super albumin can be transmitted through mucous membranes, and research is now being conducted into the possibility of delivering albumin-containing drugs to the mucous membranes of the nose, lungs or intestines, without syringes.
Conflicts of interest: Andersen is a co-inventor and has the right to royalty payments if the technology is commercialized.